Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 360
Healthy volunteers: no

Brief summary:
Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.

Detailed description:

Arms:
arm 1: linagliptin 5 mg once daily arm 2: matching placebo for linagliptin dose once daily

Interventions: intervention 1: Placebo intervention 2: Linagliptin 5mg
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: